NCT03428178

Efficacy Study of Gene Therapy for The Treatment of Acute LHON Onset Within Three Months

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: Bin Li · Academic / Other
• Sex: All
• Age: 8 Years – 60 Years
• Healthy volunteers: Accepted

Summary

Efficacy Study of Gene Therapy for The Treatment of Acute Leber's Hereditary Optic Neuropathy (LHON) onset within three months

Detailed description

Leber's Hereditary Optic Neuropathy (LHON) is a maternally inherited ocular disorder associated with a mutation in mtDNA .The disease is a common cause of teenaged blindness in both eyes for which there is currently no effective treatment. In 2008, the investigators recognized that gene therapy for LHON could be performed not only theoretically but technically. The investigators have been carring out a series of basic and clinical studies from constructing the vectors to identifying and mitigating safety issues . After performing several animal experiments, the investigators had moved into clinical trials. In 2011, the investigators performed the first LHON gene therapy trial in the world, which was registered in December 2010 at ClinicalTrials.gov (Registration number: CT01267422) and was a preliminary study to verify the safety and efficacy of gene therapy for LHON . In the 36-month follow-up, the investigators found that six out of nine patients have vision improvement obviously and no adverse events were observed. This is a multi - center , prospective study of 120 patients with the G11778A mutation in Mt-DNA.This clinical trial recruited 20 patients with the 11778 mutation of MT-DNA onset within three months,20 between 3 to 6 months,20 between 6 to 12 months,20 between 12 to 24 months,20 between 24 to 60 months,and 20 over 60 months.. All patients will be treated with a Single vitreous cavity injection of recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4)（0.05ml), with dose 1 × 10\^10 vg/0.05 mL .The eye of treatment is up to the time of onset. The visual acuity, visual field,visual evoked potential （VEP）,optical coherence tomography（ OCT）, electroretinograms(ERG), retinal nerve fiber layer(RNFL)and Liver and kidney function in plasma were compared after treatment at 1,2,3,6and 12 months interval.

Conditions

• Acute LHON
• Onset Within Three Months
• Onset Between 3 to 6 Months
• Onset Between 6 to 12 Months
• Onset Between 12 to 24 Months
• Onset Between 24 to 60 Months
• Onset Over 60 Months

Interventions

Type	Name	Description
DRUG	rAAV2-ND4	rAAV2-ND4 of vitreous cavity injection

Timeline

• Start date: 2018-01-08
• Primary completion: 2018-12-06
• Completion: 2020-12-30
• First posted: 2018-02-09
• Last updated: 2020-07-29

Locations

1 site across 1 country: China